Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer-Reference-Cited by-同舟云学术

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

Published:2024-03-22 Issue:11 Volume:130 Page:1783-1794
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Haratani Koji^ORCID,Nakamura Atsushi,Mamesaya Nobuaki,Sawa Kenji,Shiraishi Yoshimasa,Saito Ryota,Tanizaki Junko,Tamura Yosuke,Hata Akito,Tsuruno Kosuke,Sakamoto Tomohiro,Teraoka Shunsuke,Oki Masahide,Watanabe Hiroshi,Tokito Takaaki,Nagata Kenji,Masuda Takeshi,Nakamura Yasushi,Sakai Kazuko,Chiba Yasutaka,Ito Akihiko^ORCID,Nishio Kazuto^ORCID,Yamamoto Nobuyuki,Nakagawa Kazuhiko,Hayashi Hidetoshi^ORCID

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02662-2.pdf

Reference44 articles.

1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5. https://doi.org/10.1126/science.aar4060.

2. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16:563–80. https://doi.org/10.1038/s41571-019-0218-0.

3. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306 https://doi.org/10.1186/s40425-019-0805-8.

4. Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13:392. https://doi.org/10.1038/s41467-022-27960-2.

5. Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov. 2022;21:495–508. https://doi.org/10.1038/s41573-021-00259-5.